Pharmaceutical & Life Sciences Deal Volume Increases 53 Percent in Q1 2014; Sets the Stage for Heightened Deal Activity in 2014, According to PwC US - 21 News Now, More Local News for Youngstown, Ohio -

Pharmaceutical & Life Sciences Deal Volume Increases 53 Percent in Q1 2014; Sets the Stage for Heightened Deal Activity in 2014, According to PwC US

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE PwC US

Pharmaceutical and Medical Device Manufacturers Continue to Drive Deal Activity

NEW YORK, May 20, 2014  /PRNewswire/ -- Pharmaceutical and life sciences (PLS) merger and acquisition (M&A) volume increased 53.1 percent in the first quarter of 2014, highlighting the expected increase in deal activity from the previous year, according to Pharmaceutical and Life Sciences Deals Insights Quarterly, a quarterly analysis of M&A trends and outlook for the PLS sector issued today by PwC US.

PwC logo.

"The first quarter of 2014 began where 2013 left off with the continuation of robust M&A activity in the PLS industry. CEOs are increasingly optimistic about their companies' prospects and are seeking opportunities to grow their businesses through adopting new technologies, optimizing shareholder value and diversifying their portfolios," said Dimitri Drone, U.S. pharmaceutical and life sciences deals leader, PwC. "We're working with clients in developing strategies to reassess and realign their portfolios in light of the evolving industry dynamics and ultimately helping to expand their businesses."

There were 49 PLS transactions in the first quarter of 2014, compared to 32 deals in the fourth quarter of 2013. Total deal value also jumped more than 20 percent to $44.9 billion in the first quarter of 2014 compared to approximately $37.2 billion in the fourth quarter of 2013. On an annual basis, deal volume and value increased 40 percent and 122.6 percent, respectively, in the first quarter of 2014 compared to the first quarter of 2013.

Thirteen divestitures were completed in the first quarter of 2014, representing a total value of $10.1 billion – a trend that may continue or accelerate in the coming quarters as PLS companies continue to look for opportunities to optimize shareholder value and develop new business models. Additionally, strategic alliances and joint ventures remain the primary vehicles for deal activity in the PLS industry.

Looking at the PLS industry sectors, medical device manufacturers remained active in deal activity with 19 total deals in the first quarter as companies are evaluating opportunities that will have an impact on their businesses through adopting new technologies to improve patient experiences and outcomes. Additionally, pharmaceutical companies represented 16 deals in the first quarter and are seeking opportunities to unlock shareholder value through divestitures while gaining strength in their core businesses.

Biotechnology companies continue to add pressure on pharmaceutical companies as they are looking to diversify their product portfolios and gain scale through M&A. After a pause in deal activity, the diagnostics and services sectors returned to the deals table through a continued focus on R&D effectiveness, advances in personalized medicine, and the emergence of new technologies – a trend that is likely to drive continued M&A interest.

"We can expect to see continued PLS M&A activity in 2014 as strong equity markets, overall economic stability, and trends within the individual sectors are creating an environment ripe for further investor interest in the industry," concluded Drone.

PwC's Deals practitioners help corporate and private equity executives navigate transactions to increase value and returns. In today's increasingly daunting economic and regulatory environment, our experienced M&A professionals assist clients on a range of transactions from smaller and mid-sized deals to the most complex transactions, including domestic and cross-border acquisitions, divestitures and spin-offs, capital events such as IPOs and debt offerings, and bankruptcies and other business reorganizations. We help clients with strategic planning around their growth and investment agendas and advise on business-wide risks and value drivers in their transactions for more empowered negotiations, decision-making and execution. We help clients expedite their deals, reduce their risks, capture and deliver value to their stakeholders and quickly return to business as usual. Our local and global deal strength is derived from over 1,500 deal professionals in 35 cities in the U.S. and over 13,400 deal professionals across a global network of firms in 75 countries. In addition, our network firm PwC Corporate Finance provides investment banking services within the U.S. For more information, visit www.pwc.com/us/deals.

About PwC's Health Industries Group
PwC's Health Industries Group (www.pwc.com/us/healthindustries) is a leading advisor to public and private organizations across the health industries, including healthcare providers, pharmaceuticals, health and life sciences, payers, employers, academic institutions and non-health organizations with significant presence in the health market. Follow PwC Health Industries at @PwCHealth.

About PwC US
PwC US helps organizations and individuals create the value they're looking for. We're a member of the PwC network of firms in 157 countries with more than 184,000 people. We're committed to delivering quality in assurance, tax and advisory services. Tell us what matters to you and find out more by visiting us at www.pwc.com/US. Gain customized access to our insights by downloading our thought leadership app: PwC's 365™ Advancing business thinking every day

Learn more about PwC by following us online: @PwC_LLP, YouTube, LinkedIn, Facebook and Google +.

© 2014 PricewaterhouseCoopers LLP, a Delaware limited liability partnership. All rights reserved. PwC US refers to the US member firm, and PwC may refer to either the PwC network of firms or the US member firm. Each member firm is a separate legal entity. Please see www.pwc.com/structure for further details.

This content is for general information purposes only, and should not be used as a substitute for consultation with professional advisors.

Logo - http://photos.prnewswire.com/prnh/20100917/NY66894LOGO

©2012 PR Newswire. All Rights Reserved.

  • More From wfmj.comMore>>

  • Man charged for urinating on Modell's grave

    Man charged for urinating on Modell's grave

    Tuesday, July 29 2014 9:58 PM EDT2014-07-30 01:58:59 GMT
    Baltimore County authorities say they will charge a man with disorderly conduct in a cemetery for allegedly urinating on the gravesite of former Baltimore Ravens owner Art Modell.More >>
    Baltimore County authorities say they will charge a man with disorderly conduct in a cemetery for allegedly urinating on the gravesite of former Baltimore Ravens owner Art Modell.
    More >>
  • Senate passes highway bill, sends it back to House

    Senate passes highway bill, sends it back to House

    Tuesday, July 29 2014 8:47 PM EDT2014-07-30 00:47:27 GMT
    The Senate is scheduled to take up legislation Tuesday to keep federal highway money flowing to states, with just three days left before the government plans to start slowing down payments.More >>
    The Senate voted Tuesday to keep federal highway money flowing to the states into December but only after rejecting the House's reliance on what lawmakers called a funding "gimmick" and moving to force a post-election...More >>
  • 1 of 2 Ohio plane crash victims not yet identified

    1 of 2 Ohio plane crash victims not yet identified

    Monday, July 28 2014 9:48 PM EDT2014-07-29 01:48:43 GMT
    FINDLAY, Ohio (AP) - Authorities in northwest Ohio are still trying to identify one of two people killed in a weekend plane crash. One of the victims in the crash near Findlay was the CEO of an Ohio manufacturing company. A coroner was trying to identify the remains of a woman killed in the crash, but the Hancock County Sheriff's Office says DNA testing may be needed. Deputies say Ralf Bronnenmeier, CEO of Grob Systems in Bluffton, was piloting the single-engine plane that crashed early Sund...More >>
    FINDLAY, Ohio (AP) - Authorities in northwest Ohio are still trying to identify one of two people killed in a weekend plane crash. One of the victims in the crash near Findlay was the CEO of an Ohio manufacturing company. A coroner was trying to identify the remains of a woman killed in the crash, but the Hancock County Sheriff's Office says DNA testing may be needed. Deputies say Ralf Bronnenmeier, CEO of Grob Systems in Bluffton, was piloting the single-engine plane that crashed early Sund...More >>
Powered by WorldNow
All content © Copyright 2000 - 2014 Worldnow and WFMJ. All Rights Reserved. For more information on this site, please read our Privacy Policy and Terms